Literature DB >> 8141851

Accelerated cholesteryl ester transfer in noninsulin-dependent diabetes mellitus.

J D Bagdade1, J T Lane, P V Subbaiah, M E Otto, M C Ritter.   

Abstract

Alterations in core lipid composition of lipoproteins in noninsulin-dependent diabetes mellitus (NIDDM) patients have suggested that the heteroexchange of neutral lipids between HDL and the apo B-containing lipoproteins may be enhanced. For this reason, we studied cholesteryl ester transfer (CET) in ten sulfonylurea-treated patients with stable NIDDM. CET measured in all NIDDM subjects with an assay of mass transfer was significantly greater than that of controls at 1 and 2 h (P < 0.001); the transfer of radiolabeled CE also was increased in a subset of four of the NIDDM group (NIDDM k = 0.21 +/- 0.04 vs. control k = 0.10 +/- 0.05; P < 0.05). A weak correlation was demonstrable between the mass of CE transferred at 1 h and diabetic control expressed as plasma fructosamine (r = 0.58, P < 0.09). To characterize this disturbance in CET further, the donor (HDL + VHDL) and acceptor (VLDL + LDL) lipoprotein fractions were isolated by ultracentrifugation at d 1.063 g/ml from NIDDM and control plasma and a series of recombination experiments were performed. Combining NIDDM acceptor with control donor fractions that contained HDL and CETP and not the combination of NIDDM donor and control acceptor lipoproteins resulted in an accelerated CET response identical to that observed in NIDDM whole plasma. This observation indicated that the abnormality in CET in NIDDM was associated with the VLDL + LDL fraction.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8141851     DOI: 10.1016/0021-9150(93)90177-v

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  9 in total

1.  Effect of the nonenzymatic glycosylation of high density lipoprotein-3 on the cholesterol ester transfer protein activity.

Authors:  B Lemkadem; D Loiseau; G Larcher; Y Malthiery; F Foussard
Journal:  Lipids       Date:  1999-12       Impact factor: 1.880

2.  Conway Memorial Lecture 2002. The dyslipidaemia of diabetes: lessons in the pathogenesis of atherosclerosis.

Authors:  G H Tomkin
Journal:  Ir J Med Sci       Date:  2002 Oct-Dec       Impact factor: 1.568

3.  Marine lipids normalize cholesteryl ester transfer in IDDM.

Authors:  J D Bagdade; M Ritter; P V Subbaiah
Journal:  Diabetologia       Date:  1996-04       Impact factor: 10.122

Review 4.  Metabolic syndrome, diabetes, and cardiovascular risk in HIV.

Authors:  Linda M Nix; Phyllis C Tien
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

5.  Apolipoprotein CI overexpression is not a relevant strategy to block cholesteryl ester transfer protein (CETP) activity in CETP transgenic mice.

Authors:  Thomas Gautier; David Masson; Miek C Jong; Jean-Paul Pais de Barros; Linda Duverneuil; Naig Le Guern; Valérie Deckert; Laure Dumont; Amandine Bataille; Zoulika Zak; Xian-Cheng Jiang; Louis M Havekes; Laurent Lagrost
Journal:  Biochem J       Date:  2005-01-01       Impact factor: 3.857

6.  Changes in high density lipoprotein subfraction lipids during neutral lipid transfer in healthy subjects and in patients with insulin-dependent diabetes mellitus.

Authors:  M C Ritter; J D Bagdade
Journal:  Lipids       Date:  1996-01       Impact factor: 1.880

7.  Altered relationship of plasma triglycerides to HDL cholesterol in patients with HIV/HAART-associated dyslipidemia: further evidence for a unique form of metabolic syndrome in HIV patients.

Authors:  Catherine N Vu; Raul Ruiz-Esponda; Eric Yang; Evelyn Chang; Baiba Gillard; Henry J Pownall; Ron C Hoogeveen; Ivonne Coraza; Ashok Balasubramanyam
Journal:  Metabolism       Date:  2013-03-19       Impact factor: 8.694

Review 8.  Management of hyperlipidaemia associated with heart transplantation.

Authors:  Klaus Wenke
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 9.  Pathophysiology of diabetic dyslipidaemia: where are we?

Authors:  Bruno Vergès
Journal:  Diabetologia       Date:  2015-03-01       Impact factor: 10.122

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.